Ypsomed Concludes License Agreement on Own Auto-injector Patents with Major Pharmaceutical Company
24 October 2007
Ypsomed is pleased to announce that it has granted to a major, globally acting pharmaceutical company a non exclusive license to use certain patents, which protect inventions of Ypsomed in the area of auto-injector technology. Ypsomed expects to receive several million Swiss Francs in license fees over the term of the concluded agreement.
Ypsomed is investing more than CHF25 million annually in research and development of new products and technologies. Today Ypsomed possesses in the area of self-injection devices, pen systems and auto-injector technology more than 219 patent families including both granted and applied patents in numerous countries. Ypsomed owns 40 patent families in the area of auto-injector technology.
Richard Fritschi, CEO of Ypsomed, was extremely pleased: "This non exclusive license agreement is a major milestone for Ypsomed and demonstrates how valuable Ypsomed's know-how and intellectual property are. Ypsomed will continue to protect their developments and technologies with patents and actively defend them."
